Results for the substance sotorasib

Sotorasib is a medication used for the treatment of non-small cell lung cancer (NSCLC) with the KRAS G12C mutation. It works by inhibiting the mutant KRAS protein, reducing tumor cell growth and proliferation.

The medication is taken orally, as directed by a doctor, usually once daily. It is important for patients to adhere to the treatment regimen and undergo regular check-ups to monitor the response to therapy.

Patients should be aware of potential side effects, such as diarrhea, nausea, or elevated liver enzyme levels. It is important to inform the doctor of any unusual symptoms.

Common side effects include diarrhea, nausea, and elevated liver enzyme levels. In rare cases, severe reactions such as hepatotoxicity or allergic reactions may occur. Patients should be informed of these risks before starting treatment.